Resolution to Approve the Prothena Business Demerger Passed at Elan EGM


Elan Corporation, plc (NYSE: ELN) announces that, at an Extraordinary General Meeting (EGM) held earlier today, the sole ordinary resolution to approve the demerger of the Prothena Business was duly passed. The full text of the resolution was included in the notice of the EGM dated November 12, 2012 which is available on the Company’s website. The details of the votes lodged by proxy are also available on

About Elan

Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit


SOURCE: Elan Corporation, plc:

Investor Relations:         Media Relations:
Chris Burns

Ph: 1-800-252-3526

David Marshall

Ph: + 353-1-709-4444

Emer Reynolds
Ph: + 353-1-709-4022
Jonathan Birt
Ph: + 44-751-559-7858

Short Name: Elan Corporation PLC
Category Code: MSC
Sequence Number: 355406
Time of Receipt (offset from UTC): 20121212T104435+0000


Elan Corporation PLC


Elan Corporation PLC